Champions Oncology
CSBR
30 hedge funds and large institutions have $42.5M invested in Champions Oncology in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 8 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.04% less ownership
Funds ownership: 42.79% → 41.75% (-1%)
12% less funds holding
Funds holding: 34 → 30 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
55% less capital inflows, than outflows
Capital inflows: $1.01M | Capital outflows: $2.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$297K |
| 2 |
Renaissance Technologies
New York
|
+$205K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$158K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$135K |
| 5 |
XTX Topco
George Town,
Cayman Islands
|
+$99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM Investors
Solana Beach,
California
|
-$694K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$653K |
| 3 |
Millennium Management
New York
|
-$300K |
| 4 |
Goldman Sachs
New York
|
-$201K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$162K |
CSBR Hedge Fund Activity: Q2 2025 in Review
30 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q2 2025, worth a combined $42.5M — down 17% from $51.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CSBR and 4 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Morgan Stanley, adding an estimated $297K. The largest seller was EAM Investors, exiting entirely with an estimated $694K sold.
- 30 institutional investors held Champions Oncology (CSBR) as of Q2 2025, down from 34 in Q1 2025.
- Funds reported $42.5M of Champions Oncology stock for Q2 2025, down 17% quarter-over-quarter.
- 4 funds opened new Champions Oncology positions in Q2 2025 and 8 closed out, a net change of -4 holders.
- The largest Champions Oncology buyer in Q2 2025 was Morgan Stanley, an estimated $297K added.
- The largest Champions Oncology seller in Q2 2025 was EAM Investors, an estimated $694K sold.
Based on aggregated 13F filings for Q2 2025.